Roche has also sponsored a series of pandemic planning workshops for businesses around the country, creating a forum for multi-sector dialogue. Insights, information and practical tools have been compiled by Roche at http://www.pandemictoolkit.com.
Roche has taken extensive steps to ensure its own business continuity and continued manufacturing of Tamiflu and other life-saving medicines during a pandemic outbreak. Roche has provided Tamiflu to all its employees in the U.S. and globally, along with medical consultation and education about disease prevention and pandemic flu.
To date, Roche U.S. has received inquiries from more than 800 U.S.-based companies, large and small in a variety of industries, with Tamiflu orders from more than 300 companies, in quantities ranging from a few hundred to hundreds of thousands of treatment courses.
For more information, businesses may contact Roche via phone: Pandemic Planning Hotline 888-394-2838, or by e-mail: Nutley.TAMIFLU_Inquiry@Roche.com.
Tamiflu, co-developed by Gilead Sciences, Inc., based in Foster City, CA, is indicated for the treatment of uncomplicated influenza caused by viruses types A and B in patients one year and older who have had flu symptoms for no more than two days. Tamiflu is also indicated for the prevention of influenza in patients one year and older. Tamiflu is not a substitute for annual early vaccination as recommended by the CDC.
Tamiflu was approved based on
Copyright©2008 PR Newswire.
All rights reserved